good preso that summarises the business strategy and current progress very well. Having three IMP's approaching market readiness for epilepsy (EU and AU), dementia (AU) and now crohns (EU) + a host in pre-clinical shows that they have not just been sitting on their heels. Strike prices for the unlisted options are aggressive at 12.5 and 15 cents by 2021.
Don't hold highest hopes for the Nutraceutical range - crowded "space" and the products seem over priced - happy to be surprised tho.
GLTA
good preso that summarises the business strategy and current...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.55M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14314 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 6587 | 2 |
View Market Depth
| Last trade - 07.00am 26/07/2024 (20 minute delay) ? |
| RGT (ASX) Chart |
Day chart unavailable